Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 587.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 318,875 shares of the company's stock after purchasing an additional 272,520 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Dr. Reddy's Laboratories were worth $5,035,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Quantinno Capital Management LP increased its stake in Dr. Reddy's Laboratories by 18.0% during the 3rd quarter. Quantinno Capital Management LP now owns 20,237 shares of the company's stock valued at $1,608,000 after purchasing an additional 3,094 shares in the last quarter. State Street Corp increased its position in shares of Dr. Reddy's Laboratories by 1.9% in the 3rd quarter. State Street Corp now owns 909,905 shares of the company's stock valued at $72,292,000 after acquiring an additional 16,641 shares during the period. Orion Portfolio Solutions LLC increased its position in shares of Dr. Reddy's Laboratories by 43.2% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 20,524 shares of the company's stock valued at $1,631,000 after acquiring an additional 6,192 shares during the period. EWA LLC purchased a new position in Dr. Reddy's Laboratories in the 3rd quarter worth $899,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Dr. Reddy's Laboratories during the 3rd quarter worth about $464,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Performance

NYSE RDY traded up $0.51 on Friday, hitting $13.22. 2,756,790 shares of the company's stock traded hands, compared to its average volume of 1,402,091. The firm's 50-day moving average price is $13.20 and its two-hundred day moving average price is $14.36. The firm has a market capitalization of $11.03 billion, a PE ratio of 21.04 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.